Abstract
Background and objectives There are no standardized benchmarks to measure productivity and compensation of transplant nephrologists in the United States, and consequently, criteria set for general nephrologists are often used. Design, setting, participants, & measurements A web-based survey was sent to 809 nephrologists who were members of the American Society of Transplantation to gather data on measures of productivity, compensation, and job satisfaction. Factors associated with higher total compensation and job satisfaction were examined. Results Of 365 respondents, 260 were actively practicing in the United States and provided data on compensationClinical productivity was assessed variably, and although 194 (76%) had their work relative value units (wRVUs) reported to them, only 107 (44%) had an established RVU target. Two hundred thirty-four respondents (90%) had fixed base compensation, and 172 (66%) received a bonus on the basis of clinical workload (68%), academic productivity (31%), service (32%), and/or teaching responsibility (31%). Only 127 respondents (49%) filled out time studies, and 92 (35%) received some compensation for nonbillable transplant activity. Mean total compensation (base salary and bonus) was $274,4606$91,509. The unadjusted mean total compensation was higher with older age and was higher for men; Hispanic and White respondents; adult care transplant nephrologists; residents of the western United States; US medical school graduates; nonuniversity hospital employees; and those with an administrative title, higher academic rank, and a higher number of years in practice. Two hundred and nine respondents (80%) thought their compensation was unfair, and 180 (70%) lacked a clear understanding of how they were compensated. One hundred forty-five respondents (55%) reported being satisfied or highly satisfied with their job. Job satisfaction was greater among those with higher amounts of compensation and US medical school graduates. Conclusions We report significant heterogeneity in the assessment of productivity and compensation for transplant nephrologists and the association of compensation with job satisfaction.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1372-1381 |
| Number of pages | 10 |
| Journal | Clinical Journal of the American Society of Nephrology |
| Volume | 17 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2022 |
Funding
E. Akalin reports consultancy agreements with CareDx and Immucor; research funding from Angion, CareDx, Immucor, and the National Institutes of Health (NIH); honoraria from CareDx and Immucor; and serving in an advisory or leadership role for CareDx and Immucor. R.D. Bloom reports consultancy agreements with Veloxis Pharmaceuticals; research funding from CareDx, CSL Behring, Natera, and Veloxis Pharmaceuticals; honoraria from Veloxis Pharmaceuticals; serving in an advisory or leadership role for Allovir, CareDx, Natera, Paladin Labs, QSant, and Veloxis Pharmaceuticals; royalties from UpToDate; and serving on the editorial board of American Journal of Kidney Diseases. D.M. Dadhania reports consultancy for the advisory boards of AlloVir Inc., CareDx, and Veloxis Pharmaceuticals; research funding from Allo-Vir Inc., NIH, and Vitaeris Inc.; serving as section editor of Nephrology Dialysis Transplantation and associate editor of Transplantation; and is an AST committee member and a member of the LiveOnNY Medical Advisory Board. J. Friedewald reports consultancy agreements with Eurofins–Transplant Genomics, Inc. and Sanofi; research funding from CSL Behring, Eurofins Viracor, Inc., Hansa Bio-Pharma, NIH, and Veloxis; honoraria from Sanofi; patents or royalties from Northwestern University/Scripps Research Institute; serving in an advisory or leadership role for Eurofins–Transplant Genomics; and speakers bureau for Sanofi. C. Klein reports consultancy agreements with CareDx, Nephrosant, Sanofi, and Veloxis Pharmaceuticals; research funding from Eurofins Viracor; honoraria from CareDx, Sanofi, and Veloxis Pharmaceuticals; royalties from UpToDate; serving in an advisory or leadership role for the LifeLink Board of Governors; and speakers bureau for Sanofi and Veloxis Pharmaceuticals. N. Leca reports consultancy agreements with CareDx, Transplant Genomics, and Veloxis Pharmaceuticals and research funding from Angion, CareDx, CSL Behring, Natera, Novartis, Transplant Genomics, and Verici. K. Nicoll reports employment with and ownership interest in TransMedics. T. Pesavento reports employment with the Katherine M. Cyran Breast Center; ownership interest in the Katherine M. Cyran Breast Center; research funding from CareDx, Natera, NIH, and Talaris; and serving in an advisory or leadership role for the LifeLine of Ohio Board of Directors, the NephrSant Advisory Board, and the Ohio Solid Organ Transplant Consortium. M. Samaniego-Picota reports consultancy agreements with CareDx, Natera, and Verici Dx; research funding from Natera and Verici DX; honoraria from CareDx and Natera; serving in an advisory or leadership role for the Gift of Life of Michigan Board of Advisors and the education committee of the Transplantation Society; serving as an AST Fellowship Committee Cochair, an AST Kidney Pancreas Community of Practice Executive committee member, a Medeor Data Safety Monitoring Board member, the National Kidney Foundation Vice Chair of the Public Policy Committee, and a Transplantation Society Education Committee member; and other interests or relationships with AST, the Gift of Life of Michigan Board of Advisors, the National Kidney Foundation as Vice Chair of the Public Policy Committee, and the Transplantation Society as an Education Committee member. J.D. Schold reports employment with Cleveland Clinic; consultancy agreements with eGenesis, NephroSant, Novartis, and Sanofi Corporation; research funding from the One Legacy Foundation; honoraria from eGenesis, NephroSant, and Sanofi Inc.; serving as a data safety monitoring board member for Bristol Myers Squibb and on the board of directors of the Lifebanc organ procurement organization; and speakers bureau for Sanofi. N. Singh reports consultancy agreements with CareDx, Mallinckrodt, Natera, Transplant Genomics, and Veloxis Pharmaceutics; research funding from CareDx and Transplant Genomics; honoraria from CareDx, Mallinckrodt, Natera, Transplant Genomics, and Veloxis Pharmaceutics; serving as the AST Kidney Pancreas Community of Practice Cochair; and speakers bureau for CareDx, Mallinckrodt, Natera, Transplant Genomics, and Veloxis Pharmaceutics. A.C. Wiseman reports employment with Centura Transplant; consultancy agreements with CareDx, Hansa, Horizon, Immucor, Meteor, Natera, Nephro-sant, and Veloxis Pharmaceutics; and speakers bureau for CareDx, Sanofi Genzyme, and Veloxis Pharmaceutics. All remaining authors have nothing to disclose.
ASJC Scopus subject areas
- Epidemiology
- Critical Care and Intensive Care Medicine
- Nephrology
- Transplantation